68Ga-FAPI-Biotin

68Ga-FAPI-Biotin is a novel diagnostic radiopharmaceutical that combines fibroblast activation protein inhibitor (FAPI) targeting with biotin. Based on the search results, I can provide the following information: ## Description 68Ga-FAPI-Biotin is a dual-targeting PET radiotracer developed for cancer imaging. It combines the FAPI component, which targets fibroblast activation protein (FAP) expressed in cancer-associated fibroblasts found in the tumor microenvironment of various cancers, with biotin, which may provide additional targeting capabilities. This radiopharmaceutical shows promise as an excellent imaging agent applicable to various types of cancer[1][3]. ## Development Status The drug is currently in early clinical development. According to the search results, 68Ga-FAPI-Biotin is in Early Phase 1 clinical trials for various types of cancer[1]. A clinical trial (NCT06740240) is currently recruiting patients to evaluate its safety, biodistribution, and radiation dosimetry in patients with various types of cancer, and to compare these results with 68Ga-FAPI or 18F-FDG imaging[1][3]. ## Developers and Manufacturers The drug was initially developed by the First Affiliated Hospital of Fujian Medical University, which is also the current active organization conducting research on this compound[1]. ## Mechanism of Action 68Ga-FAPI-Biotin targets fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts in the stroma of more than 90% of human epithelial cancers, while its expression in healthy tissues is negligible[8]. The biotin component may provide additional targeting capabilities, making it a dual-targeting agent[3]. ## Clinical Applications The current clinical trial is investigating the use of 68Ga-FAPI-Biotin PET/CT in patients with various types of cancer. The study aims to observe the safety, biodistribution, and radiation dosimetry of 68Ga-FAPI-Biotin and compare the results with 68Ga-FAPI or 18F-FDG imaging to evaluate its dosimetric characteristics and diagnostic efficacy[1][3]. Other FAPI-based radiotracers have shown promising results in imaging various cancers, including breast cancer, where they demonstrated excellent imaging characteristics and added diagnostic value for local breast cancer, lymph nodes, and whole-body staging[5]. FAPI-based imaging has also been investigated in rheumatoid arthritis, where it showed potential as a predictor of treatment response[4]. The development of 68Ga-FAPI-Biotin represents an advancement in the field of radiopharmaceuticals, potentially offering improved diagnostic capabilities for various types of cancer through its dual-targeting mechanism.